Arpida

Arpida AG (SIX: ARPN) was a Swiss biopharmaceutical company headquartered in Reinach, near Basel, Switzerland, founded in 1997, focused on novel antibiotics to combat growing microbial resistance. Its lead product candidate was intravenous iclaprim, targeting severe infections including MRSA. After a Phase II pneumonia trial was halted in late 2008, the company cut roughly 75% of its workforce and restructured around its key asset. Arpida subsequently underwent a reverse merger and became Evolva Holding AG, ending its existence as an independent company.